Christopher A. Viehbacher is the President and Chief Executive Officer of Biogen Inc., a leading biotechnology company focused on developing therapies for neurological and neurodegenerative diseases. With an extensive background in the pharmaceutical industry, Viehbacher brings a wealth of experience and strategic vision to his role at Biogen. Prior to joining Biogen, he served as the CEO of Sanofi, a global healthcare leader, from 2008 to 2014. During his tenure at Sanofi, Viehbacher successfully led the company through a period of significant growth and transformation, implementing a patient-centric approach and expanding the company's global presence. Viehbacher's career in the pharmaceutical industry spans over three decades, beginning with his early work at GlaxoSmithKline, where he held various leadership positions across different regions, including Europe, Asia, and the United States. His strategic insights and ability to drive innovation have been instrumental in his success throughout his career. At Biogen, Viehbacher is responsible for guiding the company's overall strategy and operations, with a focus on advancing the development and commercialization of innovative therapies for patients with serious neurological conditions, such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Under Viehbacher's leadership, Biogen continues to be at the forefront of the biotechnology industry, investing in research and development to bring new treatments to market. His commitment to improving patient outcomes and his ability to foster a culture of innovation have solidified Biogen's position as a leader in the fight against neurological disorders. With Viehbacher at the helm, Biogen is well-positioned to continue its mission of transforming the lives of patients and their families through groundbreaking science and a patient-centric approach.